Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623077 · ClinicalTrials.gov registry record · Phase 1
MT2004-30: Tomotherapy for Solid Tumors
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00623077 is a Phase 1 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 23 participants.
The verdict
NCT00623077, a Phase 1 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.
Interventions
- DRUG etoposide
- DRUG melphalan
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG busulfan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2005-08 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623077
The ClinicalTrials.gov registry entry for NCT00623077 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which etoposide is the first listed.
NCT00623077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623077 about?
NCT00623077 is a clinical study titled "MT2004-30: Tomotherapy for Solid Tumors". RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is stud...
What is the current status of trial NCT00623077?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2005-08. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00623077?
The interventions under investigation include: etoposide (DRUG), melphalan (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG).
Who is sponsoring clinical trial NCT00623077?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.